Bad news Ironwood discontinues the development of MD-7246 after it failed the Phase 2B clinical trial assessing abdominal pain in IBS-D. I post it here since it was supposed to be developed for IBS-C and IBS-M as well. It was a DR forumlation of Linzess (linaclotide) targeting specifically abdominal pain and not motility. Given the previously weak data I was not surprised. Let's hope other treatments are more successfull.